Chikungunya Vaccines
Recently licensed viral vaccines
This page catalogs 2 chikungunya vaccine products. Chikungunya vaccines are among the newest additions to the licensed vaccine portfolio, with both products receiving FDA approval in 2023–2025 for adults at increased risk of exposure.
Last updated: April 2026.
Chikungunya Vaccine Catalog
| Trade Name | Generic Designation | Manufacturer | Vaccine Type | Regulatory Status & Year | Key Notes |
|---|---|---|---|---|---|
| IXCHIQ | Chikungunya vaccine, live-attenuated (VLA1553) | Valneva | Live-attenuated viral | FDA Licensed, 2023 | First chikungunya vaccine approved |
| VIMKUNYA | Chikungunya vaccine, recombinant | Bavarian Nordic | Recombinant | FDA Licensed, 2025 | Second US-licensed chikungunya vaccine |
Sources
Regulatory data sourced from FDA CBER Vaccines Licensed for Use in the United States (March 2026). Catalog scope informed by Khan, Shaz, The Ultimate Vaccine Timeline.